Skip To Main Content
Shannon Brownlee on Muck Rack

Shannon Brownlee

Washington, D.C.
As seen in: Color Research & Application, HuffPost, The Washington Post, Wiley, National Geographic, The Atlantic, BMJ Quality & Safety, POLITICO, Scientific American, Slate and
Senior Advisor to president of Lown Institute, author of Overtreated, member of @RightCareNow, but mostly a potter
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shannon

Contact Shannon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Will the new FDA fix the old FDA?

|
By Jeanne Lenzer Verified, Shannon Brownlee
| buff.ly
Jeanne Lenzer, freelance journalist, Shannon Brownlee, freelance journalist New York jeanne.lenzer{at}gmail.com Donald Trump’s government vowed to fix longstanding problems with the Food and Drug Administration. Almost a year into Trump’s second term, how is the FDA faring? Jeanne Lenzer and Shannon Brownlee report A string of scandals in recent decades has led to sharp criticism of the relationship between the US Food and Drug Administration (FDA) and pharmaceutical and medical device companies.
Open in Who Shared Issue with article?

How Big Pharma Turned FDA Approval Into a Rubber Stamp

|
By Shannon Brownlee, Jeanne Lenzer Verified
| Reader Supported News
The Food and Drug Administration, once a powerful regulatory agency, has been compromised by its cozy relationship with Big Pharma. Despite feigned concern for public health, the Trump administration is only worsening the agency’s decline. Alberto Espay was not prepared for how his world would be upended when he published a study on the number of people who have died while taking new, high-profile Alzheimer’s drugs.
Open in Who Shared Issue with article?

How Big Pharma Turned FDA Approval Into a Rubber Stamp

|
By Shannon Brownlee
| Jacobin Verified
Alberto Espay was not prepared for how his world would be upended when he published a study on the number of people who have died while taking new, high-profile Alzheimer’s drugs. Last October, the neurology professor and his colleagues posted the results of their study online, writing that patients taking Aduhelm and Leqembi were two to nearly three times as likely to die as those treated in the clinical trials.
Open in Who Shared Issue with article?
See all 82 licensed articles (90 Total)